Engitix

Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix’ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.

Domain

engitix.com

Employees

51-100

Last Funding

$25.0M

Founded

2015

Frequently Asked Questions

What technologies does Engitix use?+

Engitix uses 14 technologies including jsDelivr, Webflow, Finsweet.

What industry is Engitix in?+

Engitix operates in the Biotechnology industry.

Where is Engitix based?+

Engitix is headquartered in United Kingdom.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026